Navigation Links
CV Therapeutics' Board of Directors Rejects Astellas Unsolicited Proposal
Date:2/20/2009

primarily focused on applying molecular cardiology to the discovery, development and commercialization of novel, small molecule drugs for the treatment of cardiovascular diseases. CV Therapeutics Europe Ltd. is the company's European subsidiary based in the United Kingdom.

CV Therapeutics' approved products in the United States include Ranexa(R) (ranolazine extended-release tablets), indicated for the treatment of chronic angina, and Lexiscan(R) (regadenoson) injection for use as a pharmacologic stress agent in radionuclide myocardial perfusion imaging in patients unable to undergo adequate exercise stress. Ranexa(R) (ranolazine prolonged-release tablets) is approved for use in the European Union as add-on therapy for the symptomatic treatment of patients with stable angina pectoris who are inadequately controlled or intolerant to first-line anti anginal therapies. CV Therapeutics also has other clinical and preclinical drug development candidates and programs.

Except for the historical information contained herein, the matters set forth in this press release, including statements as to research and development and commercialization of products, are forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially, including operating losses and fluctuations in operating results; capital requirements; regulatory review and approval of our products; the conduct and timing of clinical trials; commercialization of products; market acceptance of products; product labeling; concentrated customer base; reliance on strategic partnerships and collaborations; uncertainties in drug development; uncertainties regarding intellectual property and other risks detailed from time to time in CV Therapeutics' SEC reports, including its Quarterly Report on Fo
'/>"/>

SOURCE CV Therapeutics, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. CV Therapeutics Reports 2008 Fourth Quarter and Full Year Financial Results
2. Sopherion Therapeutics Secures $55 Million in Series C Funding
3. Amicus Therapeutics Announces Change to Board of Directors
4. Opsona Therapeutics Closes EUR18M Funding
5. Sirion Therapeutics Partners With Advanced Vision Research (TheraTears(R)) to Promote Products for Retinal and Meibomian Gland Health
6. First Multiple Dose Clinical Trial of TorreyPines Therapeutics Oral Compound NGX426 Demonstrates Compound Is Safe and Well-Tolerated
7. United Therapeutics to Announce 2008 Fourth Quarter and Annual Financial Results Before Market Open on Tuesday, February 17, 2009
8. Northwest Biotherapeutics Secures $700,000 Equity Financing
9. iCo Therapeutics Closes $1.3 Million Private Placement
10. Cell Therapeutics, Inc. (CTI) BIO CEO Presentation to be Webcast
11. Amicus Therapeutics Announces Fourth Quarter and Full Year 2008 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)... MA (PRWEB) December 23, 2014 Earlier ... Dr. James L. Sherley, director of the Adult Stem ... on an often overlooked and under appreciated unique property ... Self-Renewal by Distributed Stem Cells: Misunderstood in the Past, ... message to congress participants. He gave the address ...
(Date:12/24/2014)... Bethesda, MD (PRWEB) December 23, 2014 ... signed into law H.R. 83, the Omnibus and ... the first time, made hydrocephalus a condition eligible ... Research Programs (CDMRP) administered by the Department of ... conjunction with its allies on Capitol Hill, is ...
(Date:12/24/2014)... The report provides basic ... definition, classification, application and industry overview. This ... and product cost structure. Production is separated ... also covers upstream raw materials, equipment, downstream ... and proposals. In the end, the export ...
(Date:12/24/2014)... report expects global cell isolation and expansion market to ... carefully analyzed data about the vital drivers, restraints, trends, ... Copy of Report @ http://bit.ly/1yUxy0T , According ... will keep witnessing growth at an impressive CAGR during ... by rapid technological advancements, government funding and investments, and ...
Breaking Biology Technology:Adult Stem Cell Technology Center, LLC’s Director Sherley's Address on What’s Holding Back Regenerative Medicine Featured on Omics Group Website 2Adult Stem Cell Technology Center, LLC’s Director Sherley's Address on What’s Holding Back Regenerative Medicine Featured on Omics Group Website 3Adult Stem Cell Technology Center, LLC’s Director Sherley's Address on What’s Holding Back Regenerative Medicine Featured on Omics Group Website 4Rare Brain Condition Now Eligible for Department of Defense Research Dollars 2Worldwide Methyl Mercaptan Market 2015-2020 Forecasts on Development & Trends Now Available at ReportsnReports.com 2The Cell Expansion Market is Expected to Reach $14.8 billion by 2019 - New Research Report by MarketsandMarkets 2The Cell Expansion Market is Expected to Reach $14.8 billion by 2019 - New Research Report by MarketsandMarkets 3
... Inc. , has announced it will price a forthcoming ... at $3.75 per share. , ,Proceeds from the ... 2006, will be used to support research and development ... and intellectual property protection. The Madison-based company, which has ...
... people should be outraged at getting a second-rate solution for ... what average consumers demand in almost every other product and ... across many products and services as the general metric for ... world class. , , Speed is good , ...
... University of Wisconsin-Madison , justified or otherwise, is ... the tree. It has world-class scientists and well-developed mechanisms ... but most of that commercialization takes place within a ... true. Just check the figures for per capita wages, ...
Cached Biology Technology:Damn the incumbents, and full speed ahead 2Damn the incumbents, and full speed ahead 3Damn the incumbents, and full speed ahead 4Entrepreneurship grant will build strong foundation 2Entrepreneurship grant will build strong foundation 3Entrepreneurship grant will build strong foundation 4
(Date:12/19/2014)... --Research and Markets ( http://www.researchandmarkets.com/research/8kmfcn/iphone_5s ) ... 5S Fingerprint Sensor - Apple/AuthenTec TMDR92 & Sapphire ... http://photos.prnewswire.com/prnh/20130307/600769 ... 2012, Apple introduced the fingerprint reading feature with ... device of Apple incorporating such a feature, called ...
(Date:12/19/2014)... MOUNTAIN VIEW, Calif. , Dec. 18, 2014 /PRNewswire/ ... the publication of a study that pinpoints fine-scale differences ... the United States . Since immigrants ... the United States has served as ... study illuminates how American history and the ongoing mixing ...
(Date:12/17/2014)... 2014 Research and Markets ( ... "Samsung Galaxy S5 - Home Button Synaptics ... offering. http://photos.prnewswire.com/prnh/20130307/600769 ... technology than the iPhone 5S, Samsung introduces for ... product. The Galaxy S5 home button ...
Breaking Biology News(10 mins):iPhone 5S Fingerprint Sensor - Apple/AuthenTec TMDR92 & Sapphire - Technology Report 223andMe Study Sketches Genetic Portrait of the United States 223andMe Study Sketches Genetic Portrait of the United States 323andMe Study Sketches Genetic Portrait of the United States 4Samsung Galaxy S5 - Home Button Synaptics Fingerprint Sensor Technology Analysis 2
... leave the pediatrician,s office if your child has strep ... treatment. A novel application for applying DNA "nanobarcodes" ... and more accurately determine what,s causing a patient,s acute ... R. Hartman, a Cornell University PhD candidate in Biological ...
... generation sequencing (NGS) and Genomatix Software GmbH, a leading ... data, announce their decision to combine their expertise and ... genome analysis and re-sequencing project services. "We are ... high level of expertise in understanding and interpretation of ...
... New Queen,s University research has shown that the growth of melanoma, ... slowed when a little known gene called MicroRNA 193b is added. ... miR-193b when he discovered that it was deficient in melanoma tumors ... The miRNA-193b gene is found in people,s DNA and was unknown ...
Cached Biology News:Instant testing for sore throats wins CIMIT prize 2Instant testing for sore throats wins CIMIT prize 3Instant testing for sore throats wins CIMIT prize 4
Improve inventory management with stainless steel red cell canisters; ensure product safety with CO2 or LN2 backup systems. A complete solution for your blood banking needs....
The mini vertical flow workbench is designed to perform PCR protocols in a particle-free environment. The built-in UV light ensures the elimination of any nucleic acid to avoid cross-contamination....
Request Info...
... Electroporator is a simple, easy to ... in bacterial and yeast applications. ... two voltages and either one mm, ... On pressing the pulse button the ...
Biology Products: